We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

46 hedge funds and large institutions have $72.8M invested in Gyre Therapeutics in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

822% more call options, than puts

Call options by funds: $83K | Put options by funds: $9K

3% less capital invested

Capital invested by funds: $75.1M → $72.8M (-$2.31M)

6% less funds holding

Funds holding: 49 → 46 (-3)

33% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 12

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
46
Holders Change
-3
Holders Change %
-6.12%
% of All Funds
1.24%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
4
Increased
8
Reduced
12
Closed
7
Calls
$83K
Puts
$9K
Net Calls
+$74K
Net Calls Change
-$207K

Top Buyers

1
DCM
DG Capital Management
New York
+$4.08M
2
ACA
Avoro Capital Advisors
New York
+$309K
3
Renaissance Technologies
Renaissance Technologies
New York
+$196K
4
AA
Ancora Advisors
Ohio
+$126K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$126K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.24M
2
BCM
Bridgeway Capital Management
Texas
-$1.23M
3
Deutsche Bank
Deutsche Bank
Germany
-$198K
4
PPA
Parametric Portfolio Associates
Washington
-$116K
5
NCCM
Nine Chapters Capital Management
New Jersey
-$55K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$18.6M – – –
NMC
2
NEA Management Company
Maryland
$12.7M – – –
RI
3
RTW Investments
New York
$7.44M – – –
DCM
4
DG Capital Management
New York
$4.47M +$4.08M +2,036 New
CCM
5
Camber Capital Management
Massachusetts
$4.35M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.65M -$1.24M -618 -27%
BIT
7
BlackRock Institutional Trust
California
$3.22M +$24.1K +12 +0.8%
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$2.11M +$54.1K +27 +3%
SCM
9
Sarissa Capital Management
Connecticut
$1.76M – – –
EC
10
EcoR1 Capital
California
$1.73M – – –
Franklin Resources
11
Franklin Resources
California
$1.71M – – –
ACA
12
Avoro Capital Advisors
New York
$1.64M +$309K +154 +26%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$1.59M +$126K +63 +10%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$1.32M +$60.1K +30 +5%
DCM
15
DAFNA Capital Management
California
$1.29M -$4.01K -2 -0.3%
Renaissance Technologies
16
Renaissance Technologies
New York
$928K +$196K +98 +30%
Deutsche Bank
17
Deutsche Bank
Germany
$598K -$198K -99 -27%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$500K – – –
Morgan Stanley
19
Morgan Stanley
New York
$457K -$48.1K -24 -10%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$362K +$12K +6 +4%
Connor, Clark & Lunn Investment Management (CC&L)
21
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$291K – – –
AIA
22
Arbor Investment Advisors
North Carolina
$288K -$2K -1 -0.8%
California Public Employees Retirement System
23
California Public Employees Retirement System
California
$262K – – –
Goldman Sachs
24
Goldman Sachs
New York
$216K -$6.01K -3 -3%
BFA
25
BlackRock Fund Advisors
California
$212K -$16K -8 -8%
1
2 3

GYRE Hedge Fund Activity: Q2 2015 in Review

46 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2015, worth a combined $72.8M — down 3.1% from $75.1M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of GYRE and 4 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 8 added.

The largest buyer was DG Capital Management, opening a new position worth an estimated $4.08M. The largest seller was Vanguard Group, cutting an estimated $1.24M.

  • 46 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2015, down from 49 in Q1 2015.
  • Funds reported $72.8M of Gyre Therapeutics stock for Q2 2015, down 3.1% quarter-over-quarter.
  • 4 funds opened new Gyre Therapeutics positions in Q2 2015 and 7 closed out, a net change of -3 holders.
  • The largest Gyre Therapeutics buyer in Q2 2015 was DG Capital Management, an estimated $4.08M added.
  • The largest Gyre Therapeutics seller in Q2 2015 was Vanguard Group, an estimated $1.24M sold.

Based on aggregated 13F filings for Q2 2015.